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Traversal from G1 to S-phase in cycling cells of budding yeast is dependent on the
destruction of the S-phase cyclin/CDK inhibitor SICL. Genetic data suggest that SIC1
proteolysis is mediated by the ubiquitin pathway and requires the action of CDC34,
CDC4, CDC53, SKP1, and CLN/CDC28. As a first step in defining the functions of the
corresponding gene products, we have reconstituted SICi multiubiquitination in DEAE-
fractionated yeast extract. Multiubiquitination depends on cyclin/CDC28 protein kinase
and the CDC34 ubiquitin-conjugating enzyme. Ubiquitin chain formation is abrogated in
cdc4t8 mutant extracts and assembly restored by the addition of exogenous CDC4,
suggesting a direct role for this protein in SICi multiubiquitination. Deletion analysis of
SICi indicates that the N-terminal 160 residues are both necessary and sufficient to serve
as substrate for CDC34-dependent ubiquitination. The complementary C-terminal seg-
ment of SICi binds to the S-phase cyclin CLB5, indicating a modular structure for SICL.
INTRODUCTION
The transition from G1 to S-phase in the budding yeast
cell cycle requires several genetic functions, including
CDC4, CDC34, CDC53, SKP1, one member of the fam-
ily of G1 cyclins (CLN1-CLN3), and one member of the
family of S-phase-promoting B-type cyclins (CLB1-
CLB6) (Goebl et al., 1988; Schwob et al., 1994; Bai et al.,
1996; Mathias et al., 1996; Schneider et al., 1996). An
elegant genetic model that accounts for the functions
of these genes in the progression from G1 to S-phase
was put forward by Schwob et al. (1994). They ob-
served that at the nonpermissive temperature in
cdc34ts, cdc4ts, and cdc53ts mutant cells, the activity of
the S-phase-promoting CLB/CDC28 protein kinase is
repressed by high levels of the CDK inhibitor SIC1
(Mendenhall, 1993; Nugroho and Mendenhall, 1994).
Normally, SIC1 is degraded as wild-type cells negoti-
ate the G1-S transition (Donovan et al., 1994; Schwob et
al., 1994). Cell cycle-regulated destruction of SIC1 fails
to occur, however, in cdc4ts, cdc34ts, and cdc53ts mu-
tants. Moreover, accumulation of SIC1 is required for
the G1 arrest phenotype of these mutants, as deletion
of SIC1 allows DNA replication to proceed in each of
these mutants (Schwob et al., 1994). These observa-
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tions suggest that CDC34, CDC4, and CDC53 promote
the cell cycle-regulated destruction of SIC1, thereby
revealing the heretofore cryptic S-phase-promoting
protein kinase activity of CLB/CDC28. More recent
work has established that SKP1, like CDC4, CDC53,
and CDC34, is also required for SIC1 destruction and
DNA replication, and the S-phase defect imposed by
certain skplts mutant alleles can be rescued by deletion
of SIC1 (Bai et al., 1996). Elimination of SIC1 also
appears to be a crucial aspect of CLN function during
G1 phase. Clearance of accumulated SIC1 and initia-
tion of DNA replication upon reversal of the cdc34ts
block requires CLN function (Schneider et al., 1996),
and cells lacking SIC1 no longer require CLN activity
for timely initiation of S-phase (Dirick et al., 1995) or
for viability (Schneider et al., 1996; Tyers, 1996).
The proposal that CDC34 promotes SIC1 degrada-
tion at the G1-S transition has considerable appeal,
because CDC34 encodes a member of the ubiquitin-
conjugating enzyme family (Goebl et al., 1988). Other
members of this family of proteins have previously
been implicated in the degradation of unstable pro-
teins (Hochstrasser, 1995) via the ubiquitin-protea-
some pathway. Ubiquitin, a small highly conserved
protein, is first activated at its C terminus by forming
a thioester bond with an El enzyme. Ubiquitin is
subsequently transesterified to a ubiquitin-conjugat-
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ing (E2) enzyme like CDC34. Finally, ubiquitin is
transferred from the E2 to a lysine residue of the target
protein, either directly or with the assistance of a
ubiquitin protein ligase (E3). Multiple cycles of ubiq-
uitin transfer result in the assembly of a multiubiq-
uitin chain on the substrate, which, in turn, targets it to
the 26S proteasome, where it is degraded. Although
the genetic data suggest that SIC1 might be the key
S-phase-inhibiting substrate of CDC34, it has not been
demonstrated if SIC1 is in fact ubiquitinated and if
CDC34 is required for its ubiquitination.
Although the sequence of CDC34 suggests that it
may promote degradation of SIC1 via the ubiquitin
pathway, it is unclear if CLNs, CDC4, CDC53, and
SKP1 contribute directly to this process. For instance,
the requirement for CLN/CDC28 kinase may be di-
rect, involving phosphorylation of either SIC1 or the
components of the ubiquitination machinery. It is
equally possible that CLN/CDC28 promotes the syn-
thesis of Gl-specific mRNA transcripts that encode
proteins involved in SIC1 turnover (Marini and Reed,
1992; Koch et al., 1996). Furthermore, the sequences of
CDC4, CDC53, and SKP1 are not homologous to El,
E2, or E3 components of known ubiquitin-dependent
proteolytic pathways, thereby raising the question as
to what their exact function is. Both CDC53 and SKP1
are members of novel gene families that are conserved
in Saccharomyces cerevisiae, Caenorhabditis elegans, and
humans (Zhang et al., 1995; Bai et al., 1996; Kipreos et
al., 1996; Mathias et al., 1996). CDC4 contains two
recognizable sequence motifs: an SKPl-binding do-
main termed the "F-box" and eight copies of the
WD-40 repeat (Neer et al., 1994; Bai et al., 1996). Ge-
netic data suggest that the products of CDC4, CDC53,
CDC34, and SKP1 interact (Bai et al., 1996; Mathias et
al., 1996). This prediction has, in part, been confirmed
by the assembly of CDC4/SKP1 (Bai et al., 1996) and
CDC53/CDC34 (Willems et al., 1996) complexes with
recombinant proteins and by the enrichment of CDC4
and CDC53 in affinity-purified preparations of CDC34
(Mathias et al., 1996). Though these interactions are
intriguing, it remains unclear whether CDC4, CDC53,
and SKP1 participate directly with CDC34 in the ubiq-
uitination of substrates or function in a downstream
process such as guiding ubiquitinated substrates to
the proteasome.
In the present study, we use DEAE-fractionated
yeast extract to demonstrate that SIC1 is efficiently
multiubiquitinated in vitro, resulting in at least 85% of
the input protein being converted to high molecular
weight ubiquitin conjugates. We observe a complete
dependence on CLN/CDC28 kinase and CDC34 for
high molecular weight ubiquitin conjugate formation.
SIC1 accumulates as a phosphoprotein in the absence
of CDC34 function and as an unmodified protein in
the absence of kinase, suggesting that phosphoryla-
tion may precede ubiquitination. The in vitro ubiquiti-
nation assay also revealed a potential ubiquitin ligase-
like function for the CDC4 gene product. Deletion
analysis of SIC1 was carried out to map sequence
elements that target it for destruction. This analysis
revealed the existence of a ubiquitination determinant
in the N terminus of SIC1 between residues 28 and 37.
The C-terminal amino acids 160-284 were dispensible
for ubiquitination but were required for binding
CLB5/CDC28, the S-phase kinase that is activated
upon SIC1 destruction.
MATERIALS AND METHODS
Preparation of Fractionated Yeast Extract
RJD885 (ura3, leu2, trpl, cln1::URA3, cln2::LEU2, cln3::URA3,
leu2::GAL-CLN3::LEU2, pep4::TRPI, cdc28::CDC28HA::HIS3, MATa)
and RJD893 (ura3, his3, trpl, clnl::URA3, cln2::LEU2, cln3::URA3,
leu2::GAL-CLN3::LEU2, cdc4, pep4::TRPI, cdc28::CDC28,itusp;HA:.HIS3,
MATa) cells grown in 2 1 of YEP-2% galactose were transferred by
centrifugation to 2 1 of YEP-2% glucose and incubated for 5.5 h at
24°C to deplete CLN3. Depleted cells were harvested at 4°C, washed
once with 200 ml of ice-cold water, and extruded as cell paste into
liquid N2. Frozen cells (3.5 g) were ground in a liquid N2-chilled
mortar for 10 min, and frozen powder was thawed on ice in 0.5
volumes of B93 [30 mM HEPES, pH 7.2, 100 mM potassium acetate,
1 mM EDTA, 1 mM MgCl2, 10% glycerol, 2mM dithiothreitol (DTT),
1 mM phenylmethylsulfonyl fluoride (PMSF)I fortified with an ad-
ditional 200 mM potassium acetate. Once thawing was complete,
extract was incubated on ice for 15 min, centrifuged (15 min, 50,000
rpm, Sorvall RP100-AT4) to yield an S135 (135,000 x g) fraction, and
frozen in liquid N2. S135 (30-45 mg/ml) was thawed; adjusted to 2
mM magnesium acetate, 2 mM CaCl2, 10 ,g/ml RNase, 20 ,ug/ml
DNase, 900 mU/ml hexokinase, and 50 mM glucose; incubated for
30 min at 16°C; and dialyzed once against 1 1 of CWB (CWB is 25
mM HEPES, pH 7.6, 25 mM NaCl; the dialysis step can be omitted
with no detrimental effect). After sedimenting insoluble protein (10
min at 135,000 x g), 96mg of protein was diluted to 25 ml with CWB
and applied to a 5-ml column of DEAE-Sepharose FF. The column
was washed consecutively with 2 column volumes of CWB, CWB
plus 50 mM NaCl, CWB plus 225 mM NaCl, and CWB plus 500 mM
NaCl. Proteins eluting at 250 mM NaCl were concentrated by pre-
cipitation with (NH4)2SO4 (80% saturation) or by centrifugal filtra-
tion in a Centriprep-10 (Amicon, Beverly, MA), resuspended in 0.75
ml of B93, and dialyzed once against 1 1 of B93. Insoluble protein
was pelleted by centrifugation (10 min at 135,000 x g), and the
supernatant (35 mg of protein in 1.0 ml; 0.25 M DEAE fraction) was
frozen in liquid N2 and stored at -80°C. Fractionation of CDC34 on
the DEAE column was monitored by immunoblotting column frac-
tions with anti-CDC34 antiserum (kindly provided by V. Chau,
Wayne State Univ.). The 250 mM NaCl eluate was essentially de-
void of CDC34, which eluted at 500mM NaCl. Although the bulk of
free ubiquitin flowed through, the 0.25 M DEAE fraction still con-
tained ubiquitin, as determined by immunoblotting.
Ubiquitination Reactions
Unless otherwise indicated, ubiquitination reactions contained 100
,ug of 0.25 M DEAE fraction, 1 ,ul of crude or 2 ,gl of DEAE-
fractionated reticulocyte or wheat germ translation reaction contain-
ing SICL, 10 ,ug of ubiquitin, 100 ng of CDC34, 100 ng of glutathi-
onine S-transferase (GST)-CLN2, and an ATP-regenerating system
(ARS; Deshaies and Kirschner, 1995). Final concentrations of salts
and other compounds were 20 mM HEPES, pH 7.2, 100 mM potas-
sium acetate, 6 mM magnesium acetate, 0.5 mM MgCl2, 2 mM DTT,
5% glycerol, 0.5 mM PMSF, 0.5 mM EDTA, 5 ,g/ml pepstatin, and
5 ,ug/ml leupeptin. Reactions were incubated at 25°C for the indi-
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cated times and processed for SDS-PAGE and fluorography as
described (Deshaies et al., 1995). Ubiquitin was obtained from Sigma
(St. Louis, MO), and GST-CLB2 (Kellogg et al., 1995), GST-CLN2
(Deshaies and Kirschner, 1995), CDC34 (Banerjee et al., 1993) and
K48R-His6-ubiquitin (Beers and Callis, 1993) were purified from
Escherichia coli as described. Methyl-ubiquitin was kindly provided
by R. King (Harvard Medical School), and purified UBC4 and RAD6
were kindly provided by V. Chau.
Preparation of SIC1 Substrates
SIC1 coding sequences from pMDM169 (Nugroho and Mendenhall,
1994) were excised as a BamHI-PstI fragment and inserted into
BamHI plus PstI-digested pGEM1, yielding pRD112. SIC1 produced
by transcription/translation of SIC1 coding sequences as described
(Deshaies et al., 1995) was used for in vitro ubiquitination reactions
either in crude form or following batch chromatography on DEAE
resin. Equivalent results were obtained by using SIC1 produced in
wheat germ or rabbit reticulocyte lysate. Fractionated SIC1 was
prepared by mixing 200 ,ul of a reticulocyte translation reaction with
250 ,ul of DEAE resin equilibrated with column buffer (CB; 30 mM
Tris, pH 8.5, 2 mM DTT, 25 mM NaCl). The resin was washed
consecutively with 3 column volumes of CB, CB plus 75 mM NaCl,
and CB plus 250 mM NaCl. SIC1 eluting in the 250 mM NaCl wash
was exchanged into 20 mM HEPES, pH 7.2, 100 mM potassium
acetate, and 2mM DTT by three cycles of dilution and concentration
in a Centricon-10.
To express epitope-tagged SIC1, the coding sequences of SICi
were excised from pRD112 and cloned into pETlld (Novagen,
Madison, WI). A 66-bp double-stranded oligonucleotide encoding a
bipartite myc-His6 epitope was inserted into a NotI site created at
the 3' end of SICI by PCR mutagenesis. These manipulations result
in the addition of the amino acid sequence RPLEEQKLISEEDLL-
RHHHHHHGP immediately upstream of the C-terminal histidine
residue of SIC1. SIC1mYC-HiS6 cloned into pETlld was used as a
template for in vitro transcription/translation as described above.
SIClmyc-His6 behaved identically to untagged SIC1 in in vitro ubiq-
uitination assays (our unpublished observations).
SIC1 transcription templates with 5' or 3' terminal deletions were
prepared using a PCR method as described (Verma et al., 1997). The
oligonucleotides used to create the indicated deletions are shown
below. To generate 5' truncations, the AN18, AN27, AN37, AN76,
and AN158 oligonucleotides were used in conjunction with NotI 3'.
The number following A refers to the number of codons deleted
from the 5' end (e.g., AN37 lacks amino acids 1-37): NotI 3', gcgg-
gatcctcaatgcggccgctcttgatccctagattg; AN18, gggttaatacgactcactatag-
gatccatgagtggcaatactagttctagtg; AN27, gggttaatacgactcactataagatct-
catatgcaaggtcaaaagacccc; AN37, gggttaatacgactcactataggatccatgtc-
acagaacctagtccctgtc; AN76, gggttaatacgactcactataagatctcatatgcctca-
acgctcgccgtttcc; and AN158, cccttaatacgactcactataggatccatatgga-
tcagacacatagaaagaag.
The NotI 3' oligonucleotide changes the sequence of the C termi-
nus of SIC1 from DQEH to DQERPH. This change did not affect the
ubiquitination of SIC1 (our unpublished results).
To generate 3' truncations, the AC24, AC74, AC98, AC125, AC155,
and AC179 oligonucleotides were used in conjunction with WT 5'.
The number following A refers to the number of codons deleted
from the 3' end (e.g., AC24 lacks amino acids 261-284): WT 5',
cccgaattcttaatacgactcactataagatctcatatgactccttccacccc; AC24, ggg-
gatcctcatttctctaccacctctcccttc; AC74, ggggatcctcaattgatgatgatgtct-
tcctcg; AC98, ggggatcctcaattttttgccaattcaaatg; AC125, ggggatcctcaat-
caaactcatctctttcaagtg; AC155, ggggatcctcattctgctgcatctatatccac; and
AC179, ggggatccctactcttcccttactgttcc.
Alkaline Phosphatase Treatment of SICi
A 10-,ul in vitro ubiquitination reaction lacking CDC34 and contain-
ing 2 ,ll of reticulocyte-translated SIC1mYC-Hi was diluted with 190
,ul of IPB (IPB; 25 mM Tris, pH 7.5, 0.1% Nonidet P-40, 100 mM
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NaCl, 1 mM EDTA, 2 mM DTT, 0.1 mM 4-(2-aminoethyl)-benzene-
sulfonyl fluoride hydrochlorine (AEBSF), 1 mM PMSF, 2.5 ,ug/ml
pepstatin, 2.5 ,tg/ml leupeptin), supplemented with 1 j,l of 9E10
ascites fluid (Evan et al., 1985) and incubated for 45 min at 4°C.
Immune complexes retrieved by incubation with anti-mouse IgGl
Sepharose beads (Sigma; 15,ul, packed volume) were washed twice
with IPB and twice with 50 mM Tris, pH 8.8. Washed beads were
resuspended in 50 mM Tris, pH 8.8, treated with 20 U alkaline
phosphatase in the presence or absence of 100 mM sodium phos-
phate, pH 8.8, at 37°C for 15 min, and processed for SDS-PAGE and
autoradiography (Deshaies et al., 1995).
Baculovirus Expression of CDC4 in Insect Cells
To generate a recombinant baculovirus expressing CDC4, the full-
length CDC4 gene contained in the plasmid pCDC4-73 (kindly
provided by B. Jensen, University of Washington, Seattle, WA) was
amplified by PCR using oligonucleotides RDO 72 (GAACGACTAG-
TACCATGGGGTCGTTTCCCTTAGC) and RDO 73 (GAACGGTC-
GACTCATGGTATTATAGTTGTCC). The resulting product was di-
gested with SpeI plus Sall and ligated into pRS306 that had been
digested with XbaI plus Sall. The PCR-derived part of CDC4 was
checked by DNA sequencing. The recombinant plasmid was di-
gested with XhoI, treated with Klenow fragment, digested with EagI,
and ligated into the baculovirus transfer vector pVL1392 that had
been digested with EagI and SmaI. The resulting transfer vector was
mixed with BaculoGold viral DNA (PharMingen, San Diego, CA)
and transfected into Sf9 insect cells. Plaques expressing CDC4 as
assayed by Western blot analysis were purified and amplified in Sf9
cells.
Cell lysates were prepared by infecting 100-mm dishes containing
107 Sf9 cells with virus at a multiplicity of infection of 10. After 43 h,
cells were harvested, washed twice with Tris-buffered saline, pH
7.5, resuspended in 1 ml of ice-cold BVL buffer (20 mM HEPES-
KOH, pH 7.2,150 mM NaCl, 0.1% Triton X-100, 5mM MgC12, 5 mM
EDTA, 2 mM DTT, 1 mM PMSF, 2 jig/ml leupeptin, 2 ,ug/ml
pepstatin), and sonicated briefly to ensure lysis. After pelleting cell
debris (15 min at 13,000 x g), the lysate was dialyzed twice for 2 h
against 1 1 of buffer B93. The dialysate was clarified by centrifuga-
tion (10 min at 13,000 x g) and stored at -80°C. Cell lysates
contained approximately 4 mg/ml total protein, approximately
0.25% of which was CDC4.
Binding of SIC1 to CLB5
Congenic strains K3819 (RJD916; ade2-1, trpl-1, canl-100, leu2-3,-
112, his3-11,-15, ura3::ADH-HA-CLB5::URA3, MATa) and W303
(RJD360; canl-100, leu2-3,-112, his3-11,-15, trpl-1, ura3-1, ade2-1,
MATa) were grown in YEPD medium, and cell extracts (5 mg
protein/ml) were prepared by agitation with glass beads in cell lysis
buffer (25 mM Tris, pH 7.5,100mM NaCl, 0.1% Nonidet P-40, 5 mM
EDTA, 1 mM EGTA, 2 mM sodium vanadate, 60 mM l3-glycero-
phosphate, 2 mM DYT, 10 mM NaF, 0.5 mM PMSF, 2 ,tg/ml
aprotinin, 2 ,ug/ml leupeptin, 2 ,ug/ml pepstatin). Each binding
reaction contained 200 ,ul (1 mg) of yeast extract, 1 ,ul of anti-HA
ascites fluid, and 2 ,ul of "normalized" wheat germ translation
product (translation products were adjusted to similar concentra-
tions by dilution with an unprogrammed wheat germ translation
reaction). Following a 60-min incubation on ice, immune complexes
were collected on a protein A matrix, washed three times with cell
lysis buffer, and analyzed by SDS-PAGE and fluorography.
RESULTS
Reconstitution of SIC1 Ubiquitination in
Fractionated Yeast Extract
A substantial body of genetic and biochemical data
indicate that the specific and regulated assembly of
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Figure 1. SIC1 is multiubiquitinated in vitro. (A) Tii
conversion of SIC1 to higher molecular mass forms by
Extract from cells arrested in G1 due to CLN deplel
tionated by chromatography on DEAE resin and
with ubiquitin (Ub), CDC34, GST-CLN2, and ARS. "5,
synthesized in reticulocyte lysate and fractionated b
matography on DEAE was added and the reaction
25°C for the indicated lengths of time. Reactions we
and samples were resolved by SDS-PAGE and proce
radiography as described (Deshaies et al., 1995). (B) I
SIC1 to high molecular mass forms requires ubiqu
SIC1 translation product was incubated 15 min in the
1) or presence (lanes 2-8) of 0.25 M DEAE fractii
CDC34, GST-CLN2, and ARS. The reactions displayed
,g), 4 (2.5 ,g), 5 (5.0 ,ug), and 6 (10 jig) were supplem(
indicated amounts of ubiquitin. Ubiquitin was omi
reaction shown in lane 3 and substituted by methyl
,ug) or the mutant K48R-ubiquitin (15 ,ug) in lane,
indicated.
multiubiquitin chains on substrate proteins targets
them for exhaustive proteolysis by the 26S proteasome
(Hochstrasser, 1995). To investigate the degradation of
SIC1, we thus sought to establish a fractionated in
vitro system that supported efficient CDC34-depen-
dent multiubiquitination. CLN2 was previously
Ub-Sicl p shown to be ubiquitinated in a CDC34-dependent
manner in crude whole-cell yeast extract (Deshaies et
al., 1995). Equivalent ubiquitination-competent crude
extracts of CLN-depleted Gl-arrested yeast cells were
applied to DEAE resin, and bound proteins eluted by
250 mM NaCl were pooled and concentrated as de-
'Ici 1 scribed in MATERIALS AND METHODS. The result-sdc ping G1 cyclin, ubiquitin, and CDC34-depleted 0.25 M
DEAE fraction sustained-upon addition of an ARS,
ubiquitin, CDC34, and in vitro-translated CLN2-
both the assembly of active CLN2/CDC28 complexes
and the CDC34-dependent ubiquitination of CLN2
(Verma et al., 1997; our unpublished observations).
The 0.25 M DEAE fraction was then tested for its
ability to ubiquitinate SIC1. 35S-labeled SIC1 transla-
tion product was prepared by in vitro transcription
followed by translation of SIC1 mRNA in rabbit re-
ticulocyte lysate, yielding a major 40-kDa product and
smaller amounts of an -38-kDa species (Figure 1A,
lane 6). Upon incubation for increasing amounts of
time with the 0.25 M DEAE fraction supplemented
with ARS, ubiquitin, CDC34, and GST-CLN2, SIC1
Ub-SIC1 was rapidly and efficiently converted to a ladder ofhigher molecular weight forms '(Figure 1A, lanes 1-5).
These modifications were catalyzed by activities
present in yeast cell extract, since SIC1 was not mod-
ified if 0.25 M DEAE fraction was omitted from the
reaction (Figure 1B, lane 1). Presumably, El and po-
tential E3s needed for SIC1 ubiquitination cofraction-
SIC1 ated in the 0.25 M DEAE cut.
Two pieces of evidence indicate that the high mo-
lecular mass forms of SIC1 produced in yeast cell
extract arose from multiubiquitination: the conversion
of SIC1 to high molecular mass forms was diminished
either if ubiquitin was omitted from the reaction (Fig-
me-dependent ure 1B, lane 3; immunoblotting indicated that the 0.25
f yeast extract. M DEAE fraction was contaminated with low levels of
tion was frac- ubiquitin) or if methyl-ubiquitin or K48R-ubiquitin
supplemented was added to the reaction (Figure 1B, lanes 7 and 8).
Sy batch chro- Methylation of the E-amino group of lysines or muta-
incubated at tion of lysine 48 in ubiquitin (Ub) blocks multiubiq-
Mre terminated uitin chain formation by preventing Ub-Ub ligation
ssed for auto- (Hershko and Heller, 1985; Chau et al., 1989). In sum,
Conversion of the data in Figure 1 demonstrate that multiubiquitina-
absence (lane tion of SIC1 in fractionated yeast extract was rapid,
on containing efficient, and highly processive. Indeed, the CDC34-
I in lanes 2 (10 dependent accumulation of multiubiquitinated SIC1
ented with the was severalfold more rapid and 5- to 10-fold more
ubdiqfuitimn t(h5 efficient than what is observed using CLN2 as a sub-
s 7 and 8, as strate (Deshaies et al., 1995; Verma et al., 1997). A
similar spectrum of high molecular weight ubiquiti-
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Figure 2. CDC34 and CDC4 are required for SIC1 multiubiquitination. (A) Ubiquitination of SIC1 requires CDC34. Enriched 35S-labeled
SIC1 translation product was incubated 15 min at 25'C in the absence (lane 1) or presence (lanes 2-5) of 0.25 M DEAE fraction supplemented
with ubiquitin (Ub), ARS, and GST-CLN2. The reaction displayed in lane 2 contained 0.5 ,ug of CDC34. CDC34 was omitted from the reaction
shown in lane 3 and substituted by 1.0 ,ug of UBC4 or 1.0 j, g of RAD6 in the reactions shown in lanes 4 and 5, respectively. (B) Ubiquitination
of SIC1 requires CDC4. 35S-labeled SIC1 translation product (lane 1) was incubated with CDC34, ubiquitin, ARS, GST-CLN2, and 0.25M
DEAE-fractionated extract (xtr) from wild-type CDC4+ (lane 2) or cdc4ts (lanes 3-9) cells; yeast extract was absent in lanes 1, 10, and 11. Lanes
4 and 5 contain cell lysate from uninfected Sf9 cells; lanes 6 and 7 contain lysate from Xenopus CDC2-expressing Sf9 cells; and lanes 8-11
contain lysate from CDC4-expressing Sf9 cells. Lanes 5, 7, and 9 contain a 1:3 dilution of the corresponding Sf9 cell lysate from lanes 4, 6, and
8, respectively. Reactions were carried out and processed as described in Figure 1A.
nated species was produced upon incubation of SIC1
in unfractionated cell extract (our unpublished re-
sults). For the remainder of the experiments, we used
fractionated cell extracts, however, as they were both
more active for SIC1 ubiquitination and more versatile
due to their dependence on CDC34 (see below).
Ubiquitination of SIC1 Requires CDC34 and CDC4
The disappearance of SIC1 at the G1-S transition in
vivo requires the activity of the ubiquitin conjugating
enzyme encoded by CDC34 (Schwob et al., 1994). Pre-
sumably due to its highly acidic C-terminal tail (Goebl
et al., 1988), CDC34 bound avidly to DEAE resin and
was eluted only at NaCl concentrations exceeding
-0.35 M, as judged by immunoblotting (our unpub-
lished data). Thus, to test whether the CDC34 ubiq-
uitin conjugating enzyme participates directly in the
multiubiquitination of SIC1, in vitro incubations were
performed with 0.25 M DEAE fraction as described
above except that CDC34 was omitted. As shown in
Figure 2A, no ubiquitination of SIC1 occurred in the
absence of CDC34 (lane 3). Instead, SIC1 accumulated
in a form that migrated with reduced mobility (by
approximately 2 kDa) as compared with the transla-
tion product (lane 1). We show later that this 2-kDa
shifted form arose from phosphorylation (see below).
The requirement for CDC34 was specific: UBC4 and
RAD6 ubiquitin-conjugating enzymes failed to cata-
lyze SIC1 ubiquitination (lanes 4 and 5). Titration ex-
periments indicated that CDC34 restored efficient
ubiquitination at concentrations as low as 30 nM
whereas UBC4 and RAD6 failed to restore ubiquitina-
tion even at 30-fold higher levels, concentrations at
which CDC34 was saturating but not inhibitory (lanes
4 and 5 and our unpublished results). By comparison,
measurements of [35S]methionine incorporation indi-
cated that ubiquitination reactions contained 1-5 nM
SICi.
To test whether CDC4 is also required for the mul-
tiubiquitination of SIC1 observed in DEAE-fraction-
ated extract, we prepared 0.25 M DEAE fraction from
CLN-depleted G1-arrested cdc4ts mutant cells. In con-
trast to the results obtained with a 0.25 M DEAE
fraction prepared from wild-type cells (Figure 2B, lane
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A .5 , B Figure 3. (A) Phosphory-
c,
0ow lation and ubiquitination of
0 >, X crude reaction immunoprecipitate SICI require CLN2. In vitro
v ubiquitination reactions as-
yeast extract - + + sembled in the absence (lane
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cipitated (lanes 4 through 6) and treated with calf intestinal alkaline phosphatase (see MATERIALS AND METHODS) in the absence (lane 5) or
presence (lane 6) of phosphate competitor, and samples were evaluated by SDS-PAGE and autoradiography.
2), the 0.25 M DEAE fraction isolated from cdc4ts cells
failed to sustain the assembly of high molecular mass
SICl-ubiquitin conjugates (lane 3). This ubiquitina-
tion defect was specific, since addition of Sf9 insect cell
lysates containing CDC4 expressed from a recombi-
nant baculovirus restored SIC1 ubiquitination (lanes 8
and 9), whereas Sf9 lysates from uninfected cells
(lanes 4 and 5) or from cells infected with a Xenopus
CDC2-expressing baculovirus (lanes 6 and 7) had no
effect. Estimates of the CDC4 concentration in Sf9
lysates (via immunoblotting) indicated that efficient
rescue of cdc4ts extract was achieved with 1-10 nM
CDC4 (our unpublished observations).
Phosphorylation and Ubiquitination of SIC1
Require CLN2
Genetic studies indicate that continuous CLN expres-
sion is needed for SIC1 turnover in cells released from
a cdc34t's conditional block (Schneider et al., 1996). Ad-
ditionally, cells with deleted CLNs can be rescued by
deleting SICI, implying that CLN-dependent inactiva-
tion of SIC1 is rate-limiting for entry into S-phase and
cell growth (Dirick et al., 1995; Schneider et al., 1996;
Tyers, 1996). To test whether CLN/CDC28 protein
kinase activity is directly required for multiubiquiti-
nation of SIC1, we assembled ubiquitination reactions
lacking exogenously added GST-CLN2. Since the 0.25
M DEAE fraction was prepared from Gl-arrested cy-
clin-depleted cells, it contained little or no CDC28-
associated protein kinase activity (Deshaies et al., 1995;
Deshaies and Kirschner, 1995). Upon addition of GST-
CLN2 or GST-CLB2, however, the 0.25 M DEAE frac-
tion generated CDC28-associated protein kinase activ-
ity, as was reported for unfractionated extracts
(Deshaies and Kirschner, 1995; our unpublished ob-
servations).
Whereas SIC1 was efficiently ubiquitinated in 0.25
M DEAE fraction supplemented with GST-CLN2 or
GST-CLB2 (Figure 3A, lanes 2 and 4), neither ubiquiti-
nation nor the 2-kDa shift in molecular mass were
observed when cyclin was omitted from the reaction
(Figure 3A, lane 3). Similarly, SIC1 ubiquitination and
the 2-kDa shift in molecular mass were significantly
reduced in reactions performed with extract prepared
from G1-arrested cdc28ts cells (our unpublished re-
sults). The cyclin-dependent 2-kDa shift in molecular
mass was due to phosphorylation of SIC1, since the
"shifted" 42-kDa form of epitope-tagged SIC1
(SIClmYcHis6) that accumulated in reactions containing
GST-CLN2 but lacking CDC34 (Figure 3B, lane 3) was
converted to the 40-kDa form upon incubation with
alkaline phosphatase (Figure 3B, lane 5). This 2-kDa
shift in molecular weight most likely arises from direct
phosphorylation of SIC1 by CDC28, since CLN2/
CDC28 complexes immunoisolated from yeast cells
can phosphorylate purified bacterially expressed SIC1
(Schwob et al., 1994; our unpublished observations).
The above data are consistent with earlier studies
showing accumulation of SIC1 as a phosphorylated
protein in cdc34ts cells as compared with cdc28 S cells
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The number following AC refers to the number of codons deleted from the 3' end (e.g., AC24 lacks the C-terminal amino acids 261-284). In
lanes 19-21 (exposed to film for a longer period of time), ubiquitination reactions were assembled fully supplemented as described above
(lane 20) or in the absence of yeast extract (lane 19) or GST-CLN2 (lane 21).
(Donovan et al., 1994; Schwob et al., 1994; Schneider et
al., 1996).
The N-Terminal Domain of SIC1 Contains a
Ubiquitination Determinant
To begin an analysis of how the CDC34 pathway
selects SIC1 as a substrate for ubiquitination, we con-
structed a series of 5' and 3' truncations of SICI by
PCR. PCR templates were transcribed and translated
in vitro, and the amount of protein translated from
each template was estimated by quantitation of SDS-
polyacrylamide gels. Equivalent amounts of wild-type
and mutant proteins were mixed with fully supple-
mented 0.25 M DEAE fraction and incubated under
standard reaction conditions. Whereas wild-type SIC1
yielded a characteristic pattern of ubiquitin conjugates
(Figure 4A, lane 2), a mutant lacking the first 37 amino
acids was a poor substrate (lane 6), suggesting that the
N terminus of SIC1 contains a determinant that is
essential for its recognition by the CDC34 pathway.
Since a truncation mutant lacking the first 27 amino
acids was only mildly defective for ubiquitination (our
unpublished results), the determinant could be nar-
rowed down to residues 28 through 37.
A complementary set of C-terminal deletions was
generated to test whether the N-terminal domain of
SIC1 was sufficient to serve as a substrate for CDC34-
dependent ubiquitination. Deletion of as many as 125
residues from the C terminus of SIC1 had only a
modest effect on ubiquitination (AC125 mutant; Figure
4B, lanes 10-12), which remained dependent upon
CDC34 and CLN2 (our unpublished data). In contrast,
removal of 30 more amino acids compromised the
ability of SIC1 to serve as a substrate for ubiquitina-
tion (AC155, lanes 13-15). Nevertheless, a deletion
mutant retaining only the first 105 amino acids of SIC1
was still ubiquitinated in vitro (AC179, lanes 16-18) in
a reaction that remained dependent on the addition of
GST-CLN2 (lanes 20 and 21). The diminished ubiquiti-
nation of the AC155 and AC179 mutants correlated
with a reduced phosphorylation-dependent mobility
shift. Since the 30 amino acid segment between amino
acids 130 and 160 does not contain any consensus sites
for CDC28-dependent phosphorylation, it is unclear if
this region contains a binding site required for inter-
action with CLN2/CDC28 or is required for proper
folding of the N-terminal domain.
Ubiquitination of SIC1 Does Not Depend upon Its
Association with CLB5ICDC28
The same truncation mutants that were used to map
ubiquitination determinants in SIC1 were also tested
for their ability to bind to CLB5/CDC28 complexes.
Wheat germ lysates containing in vitro-translated[35S]methionine-labeled wild-type or mutant SIC1
proteins were mixed with either control yeast extract
or yeast extract containing hemagglutinin-tagged
CLB5 (CLB5HA). CLB5HA and associated proteins
were then retrieved by immunoprecipitation with an
anti-hemagglutinin monoclonal antibody (anti-HA),
and the immune complexes were evaluated by SDS-
PAGE and fluorography (Figure 5). Whereas SIC1 mu-
tants lacking as few as 37 residues from the N termi-
nus were poor substrates for the CDC34 pathway
(Figure 4A, lane 6), deletion of up to 160 residues from
the N terminus had no effect on the interaction be-
tween SIC1 and CLB5HA (Figure 5 bottom, lanes 7-9).
In contrast, deletion of 24 residues from the C termi-
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Figure 5. The C-terminal domain of SIC1 is both necessary and
sufficient for binding to CLB5. 35S-labeled SIC1 truncation mutants
generated by transcription/translation of mutant PCR-derived tem-
plates were incubated with extract from yeast cells expressing either
untagged or HA-tagged CLB5. CLB5HA-associated proteins were
retrieved by immunoprecipitation with anti-HA monoclonal anti-
body 12CA5 and detected by SDS-PAGE followed by autoradiog-
raphy. I refers to the input fraction, B refers to the bound fraction
from reactions containing CLB5HA extract, and C refers to the
bound fraction from reactions containing untagged CLB5 extract. In
each set of lanes, the antibody-enriched fractions B and C were
overloaded twofold with respect to the input fraction. Top, C-
terminal truncation mutants deleted for the indicated number of
amino acids from the C terminus (e.g., AC24 lacks amino acids
261-284). Bottom, N-terminal truncation mutants deleted for the
indicated number of amino acids from the N terminus (e.g., AN 76
lacks amino acids 1-76).
nus of SIC1 (AC24) inactivated its ability to bind
CLB5HA (Figure 5 top, lanes 3 and 4) but had little or
no effect on SIC1 ubiquitination (Figure 4B, lane 6).
DISCUSSION
We report herein the reconstitution of SIC1 ubiquiti-
nation in extracts from budding yeast cells. Assembly
of multiubiquitin chains on SIC1 in vitro required the
E2 enzyme CDC34, a potential E3 subunit known as
CDC4, and cyclin-dependent protein kinase activity.
The N-terminal domain of SIC1 was both necessary
and sufficient to direct CDC34- and cyclin-dependent
ubiquitination of SIC1. In contrast, the C-terminal do-
main mediated the association of SIC1 with CLB5/
CDC28.
Factors Required for SIC1 Ubiquitination
Previously, it had been shown in vivo that cdc4ts,
cdC34ts, cdc53ts, skplts, and CLN-deficient mutants fail
to initiate both S-phase and SIC1 proteolysis (Goebl et
al., 1988; Schwob et al., 1994; Bai et al., 1996; Mathias et
al., 1996; Schneider et al., 1996). Given that deletion of
SICI relieves the S-phase block in these mutants, it
was proposed that CDC34, CDC4, CDC53, SKP1, and
CLNs promote the initiation of DNA replication by
specifying the elimination of SIC1 (Schwob et al.,
1994). The results presented herein provide strong
support for this model and suggest that CDC4 and
CDC34 promote SIC1 degradation by directly cata-
lyzing the assembly of multiubiquitin chains upon
SIC1. The results also prompt the question of whether
CDC53 and SKP1 are required for SIC1 multiubiquiti-
nation. Although cdc53ts mutant extracts were defec-
tive for SIC1 ubiquitination, we were unable to rescue
them with Sf9 insect cell lysates containing CDC53
expressed from a recombinant baculovirus. We did
not test skpl mutant alleles since their SIC1 proteolysis
defect appears to be rather leaky (Bai et al., 1996). We
have shown, however, that recombinant SKP1 and
CDC53 are required for CDC4/CDC34/CLN-depen-
dent ubiquitination of SIC1 in crude insect cell lysates
(Feldman et al., unpublished results).
How Does CDC4 Promote the CDC34-dependent
Ubiquitination of SICl?
The sequence of CDC4 provides little clue as to how it
promotes SIC1 multiubiquitination. CDC4 contains
two recognizable motifs: an SKPl-binding domain
known as an F-box and eight copies of the WD-40
repeat (Neer et al., 1994; Bai et al., 1996). The crystal
structure of the ,B-subunit of transducin reveals that its
seven WD-40 repeats fold into a 13-propeller structure
with seven blades evenly distributed about a central
axis. This structure provides a platform for interaction
of the 13-subunit with the a- and y-subunits of trans-
ducin (Wall et al., 1995; Lambright et al., 1996; Sondek
et al., 1996). Likewise, the WD-40 repeats of CDC4 may
fold into a structure that promotes interactions be-
tween CDC4 and other ubiquitination factors or sub-
strates.
Multiubiquitination of substrates that are degraded
by the ubiquitin-dependent proteolytic pathway often
requires E3 enzymes or accessory factors. Surpris-
ingly, the two most well-studied E3s UBR1 (Bartel et
al., 1990) and E6-AP (Huibregtse et al., 1993) are not
homologous to each other or to CDC4. Furthermore,
CDC4 lacks the conserved cysteine-containing motif
that has been implicated in the ubiquitination-promot-
ing activity of E6-AP and its homologs (Scheffner et al.,
1995). An understanding of the mechanism of action
of CDC4 in the ubiquitination of SIC1 awaits a de-
tailed dissection of this process.
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How Do CLNs Promote the Ubiquitination of SICl?
The accumulation of SIC1 is under cell cycle control.
SIC1 begins to accumulate in telophase as the decline
in CLB/CDC28 protein kinase activity enables an in-
crease in SIC1 transcription due to nuclear transloca-
tion of the transcription factor SWI5 (Chau et al., 1989).
During early (pre-START) G1 phase, newly synthe-
sized SIC1 is stable and can persist for long periods of
time in cells arrested prior to START by mutations or
nutrient starvation (Mendenhall et al., 1987; Schwob et
al., 1994). Upon traversal of START, active CLN/
CDC28 complexes are assembled and SIC1 is de-
graded shortly thereafter (Schneider et al., 1996). Deg-
radation of SIC1 depends upon CLN/CDC28 activity,
as SIC1 persists in cdc28ts and CLN-depleted cells
(Schwob et al., 1994; Schneider et al., 1996). Whereas
many of the processes downstream of START may be
activated by the CLN/CDC28-dependent synthesis of
new proteins, the results presented herein argue that
CLN/CDC28 enables SIC1 destruction by a direct
mechanism. CLN/CDC28 may promote SIC1 ubiquiti-
nation and degradation by directly phosphorylating
SIC1 and rendering it susceptible to ubiquitination by
a constitutively active CDC34 pathway, by activating
an essential component of the CDC34 ubiquitination
pathway, by inactivating an inhibitor of the CDC34
pathway, or by serving to bridge the assembly of SIC1
with ubiquitination factors such as CDC53 (Willems et
al., 1996). Experiments designed to distinguish conclu-
sively between these four possibilities are currently
underway.
How Does the G1-S Transition Work?
The observations reported herein raise several ques-
tions about the mechanism of the G1-S transition in
vivo. If CLN/CDC28 activity directly triggers SIC1
ubiquitination and subsequent proteolysis, does the
rate of SIC1 destruction (and, conversely, the level of
CLB5/CDC28 activity) mirror the rate of CLN accu-
mulation or are there mechanisms that restrain SIC1
proteolysis until CLN/CDC28 activity exceeds a
threshold? Since siclA cells enter S-phase precociously
(Schneider et al., 1996), it seems plausible that there
exists a window of time in G1 phase between the
accumulation of SBF- and MBF-promoted gene prod-
ucts, such as CLN1,2 and CLB5, and the degradation
of SIC1 (Dirick et al., 1995). If this is so, then how might
SIC1 destruction be restrained in cells with active
CLN/CDC28? Perhaps the ability of CLN/CDC28 to
activate SIC1 destruction is opposed by a potent phos-
phatase; this possibility is supported by the observa-
tion that degradation of SIC1 upon reversal of the
cdc34ts mutant block requires the continuous synthesis
of CLN protein (Schneider et al., 1996).
One factor that may contribute to the sharpness of
the G1-S transition in vivo is the potential for positive
feedback in the degradation of SIC1. Since multiubiq-
uitination of SIC1 in vitro can be triggered by CLB2/
CDC28 (Figure 3A, lane 4) and CLB5/CDC28 (Feld-
man, unpublished data), an initial burst of SIC1
destruction triggered by CLN/CDC28 would lead to
the emergence of a small pool of liberated CLB5/
CDC28 complexes, which in turn could positively feed
back to accelerate the rate of SIC1 ubiquitination and
degradation. A detailed understanding of the relation-
ship between CLN/CDC28 activity and the dynamics
of the G1-S transition in vivo would be facilitated by
the development of methods to monitor in real time
the degradation of SIC1 in single cells.
Modular Organization of SIC1
The N-terminal ubiquitination domain of SIC1 con-
tains a high density of potential CDC28 phosphoryla-
tion sites-there are seven (S/T)P dipeptides within
the first 81 amino acids-and an N-terminal fragment
containing the first 105 amino acids of SIC1 is a sub-
strate for CLN2/CDC28-dependent phosphorylation.
Aside from potential phosphorylation sites, what
other determinants within the N-terminal domain of
SIC1 might target it for CDC34-dependent ubiquitina-
tion? SIC1 has been reported to contain PEST se-
quences located at amino acids 37-49 (PEST score
-2.0), 115-141 (PEST score -2.1), and 198-212 (PEST
score +2.0) (Nugroho and Mendenhall, 1994; Rech-
steiner and Rogers, 1996). PEST sequences are compo-
sitional elements that are rich in proline, glutamic
acid, serine, and threonine; they are often found in
unstable proteins. According to Rechsteiner and Rog-
ers (1996), however, only segments with scores above
zero are normally considered as possible PEST re-
gions. The three PEST elements within SIC1 are ap-
parently not sufficient to direct its ubiquitination, since
SIC1 AN37 is poorly ubiquitinated. Moreover, the
SIC1 AC125 C-terminal truncation mutant, which
lacks the only one of the three PEST regions with a
positive score, is nevertheless a good substrate for
CDC34-dependent ubiquitination. Since SIC1 AN27 is
ubiquitinated with moderate efficiency (our unpub-
lished observations) and SIC1 AN37 is a poor sub-
strate, residues 28-37 provide an essential ubiquitina-
tion determinant. The nature of the signal contained in
this segment is unclear at present. It is unlikely to be
sufficient as a destruction signal however, since we
have created mutations elsewhere in the N-terminal
domain of SIC1 that eliminate ubiquitination (our un-
published results). A complete delineation of the se-
quence elements that specify SIC1 ubiquitination will
require a more extensive mutagenic analysis of the
N-terminal domain of SIC1.
Deletion analysis revealed that a C-terminal 126
amino acid segment of SIC1 is sufficient to bind CLB5/
CDC28 complexes and that the C-terminal 24 amino
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acids of SIC1 are absolutely essential for this interac-
tion. It is interesting to note that this extreme C-termi-
nal portion of SIC1 contains a copy of the "ZRXL"
motif (KRRL), which has been implicated as a cyclin/
CDK2 recognition determinant (Adams et al., 1996).
Mutant A- and B2-type cyclins that fail to bind CDC2
are poor substrates for ubiquitin-mediated proteolysis
during anaphase (Stewart et al., 1994). In contrast, a
mutation (SIC1 AC24) that disrupts the interaction
between SIC1 and CLB5/CDC28 has no discernible
effect on SIC1 ubiquitination. Unlike cyclins, which are
normally present in amounts substoichiometric with
respect to CDC2, the concentration of SIC1 most likely
exceeds that of CLB/CDC28 complexes in G1 cells.
That SIC1 can be ubiquitinated regardless of whether
it is bound to CLB5/CDC28 would ensure that the
entire pool of SIC1 is synchronously destroyed at the
G1-S transition, thereby preventing a pool of mono-
meric stable SIC1 from quenching the activity of
CLB5/CDC28 complexes that had just been liberated
by the destruction of bound SIC1 molecules.
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